University of Electronic Science and Technology of China
Phase
Not applicable
Started
2026-01-24
Last updated
2026-02-23
Condition(s) studied
Healthy Adult Male
Investigational drug(s) / intervention(s)
placebo (compared to vasoconstrictor)vasoconstrictor (Otrivin)placebo (compared to oxytocin)oxytocin
placebo (compared to vasoconstrictor): intranasal administration of placebo (4 sprays of 0.9% saline and glycerin)
vasoconstrictor (Otrivin): intranasal administration of vasoconstrictor (4 sprays of 0.9% Otrivin)
placebo (compared to oxytocin): intranasal administration of placebo (24 IU)
oxytocin: intranasal administration of oxytocin (24IU)
Study summary
The main goal of this study is to investigate the modulatory effects of intranasally administrated oxytocin on the processing of emotional stimuli and its acting routes.
Eligibility
Sex
MALE
Min age
18 Years
Max age
30 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy subjects without past or current psychiatric or neurological disorders
Exclusion Criteria:
* History of head injury.
* Medical or psychiatric illness.
* Subjects take a certain drug for a long period of time.
* Subjects have metal implants in their bodies.
Primary outcome measure(s)
Brain activity in response to emotional stimuli during task-based fMRI scanning — 1 hour Subjects receive task fMRI scanning after treatment. The investigators will compare the activation differences in the brain, specifically focusing on the amygdala, among three groups.
Changes in plasma oxytocin concentrations — After finishing questionnaires and 30-minute post-treatment Blood samples will be collected two times, with one sample collected after finishing questionnaires and the other one 30-minute post-treatment.
Trial sites (1)
Facility
City
Region
Status
University of Electronic Science and Technology of China (UESTC)
Chengdu
Sichuan
Recruiting
More University of Electronic Science and Technology of China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.